Gemini Therapeutics, Inc. GMTX
1.35 +1.35
Day range unavailable
52-week range unavailable
- Market cap
- 58.49M
- Shares out
- 43.33M
- Forward P/E
- -5.19
- Beta
- -0.12
- Analysts
- Hold
- Price target
- 1.50 (+11.1%)
- Earnings date
- Nov 10, 2022
No chart data for this range yet.
Key statistics
- Enterprise value
- -43.24M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.56
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -23.05M
- Total cash
- 101.74M
- Total debt
- 0
- Return on equity
- -35.38%
- Short % of float
- 6.51%
- 50-day average
- 16.67
- 200-day average
- 15.75
Analyst view
Consensus: hold
Hold
Price target (mean) 1.50
Ratings (-1m) 1 0 buy · 1 hold · 0 sell
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 10, 2022
Expected Nov 10, 2022. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 10, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -0.20 | — | — | — |
| May 6, 2022 | Mar 1, 2022 | -0.20 | — | — | — |
| Mar 10, 2022 | Dec 1, 2021 | -0.50 | — | — | — |
| Nov 15, 2021 | Sep 1, 2021 | -0.47 | — | — | — |
| Aug 12, 2021 | Jun 1, 2021 | -0.42 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 11, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Mar 3, 2022 | SVB Leerink | down | Outperform | Market Perform |
| Mar 1, 2022 | Jefferies | down | Buy | Hold |
| Jan 24, 2022 | SVB Leerink | main | — | Outperform |
| Dec 20, 2021 | SVB Leerink | main | — | Outperform |
| Dec 15, 2021 | HC Wainwright & Co. | init | — | Buy |
About Gemini Therapeutics, Inc.
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- geminitherapeutics.com
News
Gemini Therapeutics Announces ASCO 2026 Analyses Supporting Aldoxorubicin's Tumor-Targeted Delivery and Cardiac-Safety Profile 
FDA reversals leave investors worrying about the fates of other experimental drugs 
iBio (NASDAQ:IBIO) versus Gemini Therapeutics (NASDAQ:GMTX) Critical Review 
Gemini Therapeutics (NASDAQ:GMTX) Shares Down 2.6% – What’s Next? 
7 Short-Squeeze Stocks for Bold Contrarians to Consider 
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, FMTX, TRQ, SGFY 
GEMINI THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Gemini Therapeutics, Inc. – GMTX 
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GMTX, MANT, ZY, LOTZ 
Gemini Therapeutics, Inc. (GMTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? 
Stocks That Hit 52-Week Lows On Tuesday
Your note
Sign in to keep a note on GMTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FORESITE CAPITAL MANAGEMENT II, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Feb 4, 2021 | 0 |
| FS DEVELOPMENT HOLDINGS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Feb 4, 2021 | 0 |
| LEONARD BRADEN MICHAEL | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 25, 2022 | 5,247,500 |
| MEYENBURG JASON PATRICK | Chief Executive Officer | Purchase | May 13, 2021 | 13,000 |
| PIEKOS BRIAN | Chief Financial Officer | Stock Award(Grant) | May 30, 2022 | 17,615 |
| TANANBAUM JAMES B | Director | Stock Award(Grant) | Feb 4, 2021 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 13.45% | 5,826,223 | 7.87M | Sep 29, 2022 |
| Atlas Venture Life Science Advisors, LLC | 12.13% | 5,254,365 | 7.09M | Sep 29, 2022 |
| Adage Capital Partners GP L.L.C. | 5.65% | 2,447,477 | 3.30M | Sep 29, 2022 |
| Foresite Capital Management V, LLC | 5.62% | 2,435,125 | 3.29M | Sep 29, 2022 |
| Foresite Capital Opportunity Management V, LLC | 5.62% | 2,435,125 | 3.29M | Sep 29, 2022 |
| Suvretta Capital Management, LLC | 5.48% | 2,372,267 | 3.20M | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios - Biotechnology | 3.35% | 1,451,207 | 1.96M | Oct 30, 2022 |
| Vanguard Total Stock Market Index Fund | 0.64% | 275,152 | 371.45K | Sep 29, 2022 |
| Vanguard Extended Market Index Fund | 0.55% | 237,759 | 320.97K | Sep 29, 2022 |
| Fidelity Extended Market Index Fund | 0.36% | 154,315 | 208.32K | Oct 30, 2022 |
| Fidelity Growth Company Fund | 0.31% | 132,474 | 178.84K | Oct 30, 2022 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.17% | 75,000 | 101.25K | Sep 29, 2022 |